| LTP001 / Novartis |
2021-000670-28: Study of efficacy and safety of LTP001 in pulmonary arterial hypertension participants |
|
|
| Not yet recruiting | 2 | 44 | Europe | LTP001, LTP001, Capsule, hard | Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG | Pulmonary arterial hypertension, Disease in which blood vessels (arteries) in the lungs are damaged. This inhibits blood flow and pressure in the lung arteries rises and eventually heart failure develops, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2022-002007-38: Extension study of efficacy and safety of LTP001 in pulmonary arterial hypertension participants Estudio de extensión de la eficacia y la seguridad de LTP001 en participantes con hipertensión arterial pulmonar |
|
|
| Not yet recruiting | 2 | 40 | Europe | LTP001, LTP001, Capsule, hard | Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG | Pulmonary arterial hypertension Hipertensión arterial pulmonar., Disease in which blood vessels (arteries) in the lungs are damaged. Thisinhibits blood flow and pressure in the lung arteries rises and eventuallyheart failure develops Enf. en la que se dañan los vasos sanguíneos(arterias) de los pulmones.Esta inhibe el flujo sanguíneo y la presión en las arterias pulmonares se eleva y finalmente se desarrolla insuficiencia cardiaca, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2021-005066-17: Study of efficacy and safety of various treatments in participants with idiopathic pulmonary fibrosis (IPF) |
|
|
| Not yet recruiting | 2 | 94 | Europe | LTP001, LTP001, Capsule, hard | Novartis Pharma AG, Novartis Pharma AG | Idiopathic pulmonary fibrosis, Lung damage with tissue scarring and thickening due to unknown causes, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT05135000: Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension |
|
|
| Completed | 2 | 47 | Europe, US, RoW | LTP001, Placebo | Novartis Pharmaceuticals | Pulmonary Arterial Hypertension | 04/24 | 04/24 | | |
NCT05764265: Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants |
|
|
| Completed | 2 | 31 | Europe, US, RoW | LTP001 | Novartis Pharmaceuticals | Pulmonary Arterial Hypertension | 04/24 | 05/24 | | |
NCT05497284: To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF |
|
|
| Active, not recruiting | 2 | 46 | Europe, US, RoW | LTP001, Placebo, Standard of Care (SoC) | Novartis Pharmaceuticals | Idiopathic Pulmonary Fibrosis | 07/24 | 08/24 | | |
